Latest Therapeutics News

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart technology, reporting promising clinical results in Crohn’s disease and GVHD, alongside a $3.5 million capital raise to fuel next-stage development.

Argenica Therapeutics has dosed the final patient in its Phase 2 trial for ARG-007 in acute ischaemic stroke, with topline results expected in Q3 2025. Meanwhile, the FDA has placed a clinical hold on its US trial application, introducing uncertainty for US development.

Nyrada Inc. is set to launch a Phase IIa clinical trial of Xolatryp™, aiming to reduce heart muscle damage in acute myocardial infarction patients undergoing PCI. The trial, planned for early 2026, follows promising Phase I safety results and strong preclinical cardioprotection data.

Invex Therapeutics has broadened its collaboration with Tessara Therapeutics to explore Exenatide’s potential in Alzheimer’s disease, while successfully renewing key orphan drug designations in Europe and the US.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase to $204 million in Q2 2025, launched its new prostate cancer imaging agent Gozellix in the U.S., and advanced key clinical trials despite an ongoing SEC inquiry.

Prescient Therapeutics has extended the closing date of its Share Purchase Plan to July 25, 2025, responding to shareholder demand and reinforcing strong participation. The oncology-focused biotech also highlights upcoming clinical milestones and ongoing investor engagement.

BTC Health has secured a $0.5 million order for its life-saving ECMO equipment from the Women's and Children's Hospital in Adelaide, marking a significant expansion of its specialised medical device network alongside Melbourne's Royal Children's Hospital.

Microba Life Sciences reports strong Q4 FY25 growth driven by record microbiome test sales and clinician adoption in Australia and the UK, while advancing its therapeutics pipeline and targeting regional break-even in FY26.

Microba Life Sciences reports record Q4 FY25 microbiome test sales in Australia and the UK, underpinned by landmark clinical studies and a $14.5 million capital raise. The company is transitioning away from legacy products to focus on high-value diagnostics, positioning for sustained growth in FY26.

dorsaVi reports transformative performance improvements from integrating RRAM technology into its biomedical sensor platforms, promising faster, more durable, and energy-efficient wearable devices.

EVE Health Group has secured regulatory approval enabling prescription access for its lead products Libbo and Dyspro in Australia, setting the stage for a commercial rollout before the end of 2025.

PYC Therapeutics reports solid progress across its four RNA therapeutic programs targeting genetic diseases, backed by a strong cash position extending runway beyond 2027.